ENTITY
Johnson & Johnson’s TREMFYA Receives FDA Approval for Ulcerative Colitis, Expanding Treatment Options
TREMFYA, guselkumab, FDA approval, ulcerative colitis, inflammatory bowel disease, Johnson & Johnson
FDA Criticizes AbbVie for Misleading Ad Featuring Serena Williams Promoting Migraine Drug Ubrelvy
FDA, AbbVie, Serena Williams, Ubrelvy, Migraine Drug, Misleading Advertising
Triple Threat: 50% of Women Delay or Skip Medical Care Due to Affordability, Access, and Negative Experiences
Women’s healthcare, Delayed medical care, Affordability issues, Access barriers, Negative healthcare experiences, Gender disparities in healthcare, Healthcare equity
F2G Secures $100M Funding for Second Attempt at FDA Approval for Novel Antifungal Drug Olorofim
F2G, antifungal drug, olorofim, FDA approval, funding, second attempt
Lilly’s Weekly Insulin Candidate Efsitora Alfa Shows Promising Results in Phase III Trials
Eli Lilly, Efsitora Alfa, Weekly Insulin, Type 1 Diabetes, Type 2 Diabetes, Phase III Trials, QWINT Studies, Diabetes Treatment
Roche’s Obesity Pill Candidate Faces Safety Concerns Amid Promising Efficacy Results
Roche, Obesity Pill, Safety Concerns, Efficacy Data, CT-996, Side Effects, Nausea, Vomiting, Gastrointestinal Issues
Sanofi Enters Radiopharmaceutical Market with $110 Million Licensing Agreement
Sanofi, Radiopharmaceuticals, Licensing Deal, RadioMedix, Orano Med, AlphaMedix, Neuroendocrine Tumors
Adicet Bio Expands into Autoimmune Diseases with Allogeneic Gamma Delta T Cell Therapy
Adicet Bio, Autoimmune diseases, Allogeneic gamma delta T cell therapy, Lupus nephritis, Systemic lupus erythematosus (SLE), Cell therapy
PanTera Secures €93M to Tackle Alpha-Emitter Isotope Shortage Amid Growing Demand
Alpha-emitters, Isotope shortage, PanTera, Cancer treatment, Radiation therapy
Novo Nordisk’s Saxenda Demonstrates Significant Weight Loss in Children Aged 6-12 in Phase III Trial
Saxenda, Novo Nordisk, pediatric obesity, weight loss, Phase III trial, EASD24